South Korea Eperisone Market was valued at USD 0.15 Billion in 2022 and is projected to reach USD 0.23 Billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030.
Eperisone, a central muscle relaxant, has become a pivotal component in South Korea's healthcare industry, addressing a spectrum of musculoskeletal conditions. Its applications span from treating neck-shoulder-wrist syndromes to alleviating musculoskeletal pain, making it indispensable in clinical settings. citeturn0search3
The rising prevalence of musculoskeletal disorders in South Korea has significantly driven the demand for effective treatments like eperisone. According to the World Health Organization, approximately 1.71 billion individuals globally suffer from musculoskeletal conditions, with low back pain affecting around 568 million people. This global trend mirrors the situation in South Korea, where an aging population and sedentary lifestyles contribute to the increasing incidence of such ailments. citeturn0search3
In response to this growing need, South Korea's pharmaceutical sector has prioritized the development and distribution of eperisone-based medications. Companies like Eisai Co., Ltd. have introduced products such as EprisanSR Capsules, designed to relieve pain and discomfort associated with acute musculoskeletal conditions, including rigidity, tension, stiffness, and muscle spasms. citeturn0search3
However, the widespread use of eperisone is not without challenges. Studies have indicated a rise in adverse drug reactions (ADRs) linked to eperisone. From 2010 to 2015, prescriptions for eperisone in South Korea surged by 44%, accompanied by a 564% increase in reported ADRs during the same period. Notably, in 2015, out of 901,255 patients prescribed eperisone, 73 cases of ADRs were reported, with 14 classified as anaphylactic reactions. citeturn0search0
The South Korean biopharmaceutical market, encompassing muscle relaxants like eperisone, is on an upward trajectory. In 2024, the market generated revenues of approximately USD 5,861.8 million and is projected to reach USD 11,005.7 million by 2030, reflecting a compound annual growth rate (CAGR) of 11.3%. This growth underscores the escalating demand for effective treatments for musculoskeletal disorders. citeturn0search2
In conclusion, eperisone plays a crucial role in South Korea's healthcare landscape, addressing the needs of patients with musculoskeletal conditions. While its efficacy is well-recognized, the associated risks necessitate vigilant monitoring and continuous research to ensure patient safety and optimize therapeutic outcomes.
Get an In-Depth Research Analysis of the South Korea Eperisone Market Size And Forecast [2025-2032]
Navipharm
Daewon
Hanmi
Eisai
Bracco
Zambon
Hunan Yada Pharmaceutical
Qingdao Guohai Biopharmaceutical
Navipharm
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Eperisone Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Eperisone Market
Tablets
Injections
Suspensions
Musculoskeletal Disorders
Neuropathic Pain Management
Postoperative Pain Relief
Pharmacies
Hospitals
Online Retail
Hospitals
Clinics
Home Care Settings
Low Dosage (e.g., 50 mg)
Medium Dosage (e.g., 100 mg)
High Dosage (e.g., 150 mg)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Eperisone Market Research Analysis
1. Introduction of the South Korea Eperisone Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Eperisone Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Eperisone Market, By Type
6. South Korea Eperisone Market, By Application
7. South Korea Eperisone Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Eperisone Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/